NO20031531L - Fremgangsmater for induksjon av kreftcelledod og tumorregresjon - Google Patents

Fremgangsmater for induksjon av kreftcelledod og tumorregresjon

Info

Publication number
NO20031531L
NO20031531L NO20031531A NO20031531A NO20031531L NO 20031531 L NO20031531 L NO 20031531L NO 20031531 A NO20031531 A NO 20031531A NO 20031531 A NO20031531 A NO 20031531A NO 20031531 L NO20031531 L NO 20031531L
Authority
NO
Norway
Prior art keywords
methods
cell death
cancer cell
tumor regression
induction
Prior art date
Application number
NO20031531A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031531D0 (no
Inventor
George Q Daley
Original Assignee
George Q Daley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Q Daley filed Critical George Q Daley
Publication of NO20031531D0 publication Critical patent/NO20031531D0/no
Publication of NO20031531L publication Critical patent/NO20031531L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20031531A 2000-10-05 2003-04-04 Fremgangsmater for induksjon av kreftcelledod og tumorregresjon NO20031531L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (2)

Publication Number Publication Date
NO20031531D0 NO20031531D0 (no) 2003-04-04
NO20031531L true NO20031531L (no) 2003-06-05

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031531A NO20031531L (no) 2000-10-05 2003-04-04 Fremgangsmater for induksjon av kreftcelledod og tumorregresjon

Country Status (14)

Country Link
US (1) US6777415B2 (enExample)
EP (1) EP1322334A2 (enExample)
JP (1) JP2004510733A (enExample)
CN (1) CN1479630A (enExample)
AU (2) AU2002211862B2 (enExample)
BR (1) BR0114430A (enExample)
CA (1) CA2424797C (enExample)
HK (1) HK1052870A1 (enExample)
HU (1) HUP0302913A3 (enExample)
MX (1) MXPA03003011A (enExample)
NO (1) NO20031531L (enExample)
NZ (1) NZ524936A (enExample)
WO (1) WO2002028381A2 (enExample)
ZA (1) ZA200302523B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
WO2002028409A2 (en) * 2000-10-05 2002-04-11 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
CN1617755A (zh) * 2001-11-30 2005-05-18 先灵公司 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
AU2003228225B2 (en) * 2002-03-01 2010-05-13 Roger Williams Hospital SHC protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
WO2007058965A1 (en) * 2005-11-11 2007-05-24 Roger Williams Hospital P66-shc as predictive marker in cancer treatment
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2098198A1 (en) 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
EP0906099A4 (en) 1996-04-03 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
CN1267291A (zh) 1997-06-17 2000-09-20 先灵公司 新的n－取代的脲的法呢基蛋白转移酶抑制剂
ATE218137T1 (de) * 1997-06-17 2002-06-15 Schering Corp Benzo(5,6)cyclohepta(1,2-b)pyridin derivate als farnesyl protein transferase inhibitoren
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
AU779008C (en) 1999-01-11 2005-06-30 Princeton University High affinity inhibitors for target validation and uses thereof
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1181013B1 (en) * 1999-04-14 2006-10-11 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
WO2002000024A1 (en) * 2000-06-30 2002-01-03 The Regents Of The University Of California New strategy for leukemia therapy
WO2002028409A2 (en) * 2000-10-05 2002-04-11 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Also Published As

Publication number Publication date
AU1186202A (en) 2002-04-15
US6777415B2 (en) 2004-08-17
CA2424797C (en) 2009-12-29
HUP0302913A3 (en) 2005-05-30
AU2002211862B2 (en) 2007-03-15
NO20031531D0 (no) 2003-04-04
ZA200302523B (en) 2004-08-24
MXPA03003011A (es) 2003-07-14
WO2002028381A2 (en) 2002-04-11
HUP0302913A2 (hu) 2003-12-29
US20020128280A1 (en) 2002-09-12
BR0114430A (pt) 2004-01-06
JP2004510733A (ja) 2004-04-08
HK1052870A1 (zh) 2003-10-03
NZ524936A (en) 2005-08-26
EP1322334A2 (en) 2003-07-02
WO2002028381A3 (en) 2003-03-27
CN1479630A (zh) 2004-03-03
CA2424797A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
MY120841A (en) Methods of inducing cancer cell death and tumor regression
NO20031531L (no) Fremgangsmater for induksjon av kreftcelledod og tumorregresjon
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
AP1599A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties.
NO963860L (no) Isoprenyl-transferase-inhibitorer
ATE375794T1 (de) Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
ATE415161T1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
CY1105477T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου
WO2001064198A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064195A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
NO20023833D0 (no) Modifiserte cytokiner for anvendelse i cancerterapi
ES2138595T3 (es) Inhibidores de citoquinas.
DE68903378D1 (de) Hemmung der zellenadhaesion.
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
ATE216892T1 (de) Inhibitor von nebenwirkungen zur krebstherapy
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
WO2001064197A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
DE69305348D1 (de) Proteintyrosinphosphatase alpha - Inhibitoren zur Tumorbehandlung
DK1162985T3 (da) Matrixproteinsammensætninger til induktion af apoptose
ECSP003417A (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
NZ509646A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
ECSP982800A (es) Metodos para el tratamiento de enfermedades proliferativas
MX9703208A (es) Tetra-y pentapeptidos substituidos inhibidores de proteina; farnesil transferasa.
UA23977A (uk) Іhгібітор росту злоякісhих клітиh
DE69812945D1 (de) Tricyclische aminooxyamide derivate als farnesyl protein transferase inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application